Posted by Michael Wonder on 29 Jul 2025
Zevra Therapeutics submits marketing authorisation application to EMA to review arimoclomol for the treatment of Niemann-Pick disease type C
28 July 2025 - Zevra Therapeutics announced the company submitted a marketing authorisation application to the EMA for the evaluation of arimoclomol for the treatment of Niemann-Pick disease Type C.
Arimoclomol has also received orphan medicinal product designation by the EMA for the treatment of Niemann-Pick disease Type C.
